HHC Crossed Into Rat Brains, Caused Anxiety, and Was Classified as Low-Toxicity

A 1:1 mixture of (9R)-HHC and (9S)-HHC reached peak blood and brain concentrations 2 hours after the highest dose (10 mg/kg). OECD 423 toxicity testing classified HHC as Category 4 (estimated lethal dose 1000 mg/kg). At 10 mg/kg, HHC reduced movement, increased anxiety-like behavior, and impaired prepulse inhibition of acoustic startle response.

Male Wistar rats received a 1:1 mixture of (9R)-HHC and (9S)-HHC via intragastric gavage at 1, 5, and 10 mg/kg. Behavioral effects assessed via open field test and prepulse inhibition. Pharmacokinetics measured in blood and brain tissue. Toxicity classified per OECD 423 protocol.

HHC is widely sold as a legal THC alternative in parts of Europe and the UK, but safety data have been almost nonexistent. This is among the first studies characterizing its pharmacokinetics, toxicity, and behavioral effects.

As novel cannabinoids like HHC proliferate in legal gray areas, basic safety data are urgently needed. This study provides an initial toxicological profile, but the anxiety-inducing and sensory-impairing effects at higher doses raise concerns about the unregulated market.

Male rats only. Used a racemic mixture rather than individual stereoisomers. Oral gavage dosing may not reflect typical human consumption routes (vaping, edibles). Acute effects only, no chronic exposure data. Limited behavioral battery.